2008-03-06 16:47:40 -

www.theragenics.com - Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the cancer treatment and surgical markets, today announced its Annual Meeting of Stockholders will be held on Thursday, May 15, 2008, at 9:00 a.m., Central Time, at Rosewood Crescent Hotel, Dallas, 400 Crescent Court, Dallas, TX 75201. The Board of Directors fixed the close of business

on March 17, 2008, as the record date for the determination of the stockholders entitled to notice of, and to vote at, the meeting. It is anticipated that the Proxy Statement, Proxy and Annual Report on Form 10-K will be mailed to the stockholders entitled to notice of and to vote at the Annual Meeting on or around April 2, 2008. This announcement serves to satisfy the public disclosure requirement of the Annual Meeting of the Stockholders.

Theragenics Corporation (NYSE: TGX) operates two business segments: its brachytherapy seed business and its surgical products business. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed(R) device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. Its surgical products business (www.cpmedical.com and www.galtmedical.com) manufactures and distributes wound closure and vascular access products. Wound closure products include sutures, needles and other surgical products with applications in, among other areas, urology, veterinary, cardiology, orthopedics, plastic surgery and dental. Vascular access includes introducers and guidewires used in the interventional radiology, interventional cardiology and vascular surgery markets. For additional information, call Theragenics' Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.

Theragenics Corporation
Frank J. Tarallo, 800-998-8479 or 770-271-0233
CFO & Treasurer
or
Lisa Rassel, 800-998-8479 or 770-271-0233
Manager of Investor Relations
www.theragenics.com